The Dangers of H.R. 3

Some members of Congress are considering a drug pricing plan – H.R. 3 – that could have devastating impacts on American patients, jobs and medical innovation. It relies on a form of price setting in which the U.S. government would determine the value of life-saving medicines based on decisions by foreign governments about which medicines are worth investing in and which ones are not – regardless of what patients and their doctors think.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.